256 related articles for article (PubMed ID: 15175641)
1. Muscle stem cells can act as antigen-presenting cells: implication for gene therapy.
Cao B; Bruder J; Kovesdi I; Huard J
Gene Ther; 2004 Sep; 11(17):1321-30. PubMed ID: 15175641
[TBL] [Abstract][Full Text] [Related]
2. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product.
Yuasa K; Sakamoto M; Miyagoe-Suzuki Y; Tanouchi A; Yamamoto H; Li J; Chamberlain JS; Xiao X; Takeda S
Gene Ther; 2002 Dec; 9(23):1576-88. PubMed ID: 12424610
[TBL] [Abstract][Full Text] [Related]
3. Efficient muscle-specific transgene expression after adenovirus-mediated gene transfer in mice using a 1.35 kb muscle creatine kinase promoter/enhancer.
Larochelle N; Lochmüller H; Zhao J; Jani A; Hallauer P; Hastings KE; Massie B; Prescott S; Petrof BJ; Karpati G; Nalbantoglu J
Gene Ther; 1997 May; 4(5):465-72. PubMed ID: 9274724
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo gene transfer to mature skeletal muscle by using adenovirus helper cells.
Kimura S; Ikezawa M; Cao B; Kanda Y; Pruchnic R; Cummins J; Huard J; Miike T; Suzuki S
J Gene Med; 2004 Feb; 6(2):155-65. PubMed ID: 14978769
[TBL] [Abstract][Full Text] [Related]
5. Construction and analysis of compact muscle-specific promoters for AAV vectors.
Wang B; Li J; Fu FH; Chen C; Zhu X; Zhou L; Jiang X; Xiao X
Gene Ther; 2008 Nov; 15(22):1489-99. PubMed ID: 18563184
[TBL] [Abstract][Full Text] [Related]
6. Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D.
Rodino-Klapac LR; Lee JS; Mulligan RC; Clark KR; Mendell JR
Neurology; 2008 Jul; 71(4):240-7. PubMed ID: 18525034
[TBL] [Abstract][Full Text] [Related]
7. Sustained expression of human apo A-I following adenoviral gene transfer in mice.
De Geest B; Van Linthout S; Collen D
Gene Ther; 2001 Jan; 8(2):121-7. PubMed ID: 11313781
[TBL] [Abstract][Full Text] [Related]
8. Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin.
Li S; Kimura E; Fall BM; Reyes M; Angello JC; Welikson R; Hauschka SD; Chamberlain JS
Gene Ther; 2005 Jul; 12(14):1099-108. PubMed ID: 15759015
[TBL] [Abstract][Full Text] [Related]
9. Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products.
Yuasa K; Yoshimura M; Urasawa N; Ohshima S; Howell JM; Nakamura A; Hijikata T; Miyagoe-Suzuki Y; Takeda S
Gene Ther; 2007 Sep; 14(17):1249-60. PubMed ID: 17581597
[TBL] [Abstract][Full Text] [Related]
10. Comparison of high-capacity and first-generation adenoviral vector gene delivery to murine muscle in utero.
Bilbao R; Reay DP; Wu E; Zheng H; Biermann V; Kochanek S; Clemens PR
Gene Ther; 2005 Jan; 12(1):39-47. PubMed ID: 15483668
[TBL] [Abstract][Full Text] [Related]
11. Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice.
Lochmüller H; Petrof BJ; Pari G; Larochelle N; Dodelet V; Wang Q; Allen C; Prescott S; Massie B; Nalbantoglu J; Karpati G
Gene Ther; 1996 Aug; 3(8):706-16. PubMed ID: 8854096
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus mediated gene transfer to skeletal muscle.
Cao B; Mytinger JR; Huard J
Microsc Res Tech; 2002 Jul; 58(1):45-51. PubMed ID: 12112422
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo gene therapy-induced endochondral bone formation: comparison of muscle-derived stem cells and different subpopulations of primary muscle-derived cells.
Shen HC; Peng H; Usas A; Gearhart B; Cummins J; Fu FH; Huard J
Bone; 2004 Jun; 34(6):982-92. PubMed ID: 15193544
[TBL] [Abstract][Full Text] [Related]
14. Promoters influence the kinetics of transgene expression following adenovector gene delivery.
Chen P; Tian J; Kovesdi I; Bruder JT
J Gene Med; 2008 Feb; 10(2):123-31. PubMed ID: 18064718
[TBL] [Abstract][Full Text] [Related]
15. Designing gene therapy vectors: avoiding immune responses by using tissue-specific promoters.
Weeratna RD; Wu T; Efler SM; Zhang L; Davis HL
Gene Ther; 2001 Dec; 8(24):1872-8. PubMed ID: 11821941
[TBL] [Abstract][Full Text] [Related]
16. Full-length dystrophin gene transfer to the mdx mouse in utero.
Reay DP; Bilbao R; Koppanati BM; Cai L; O'Day TL; Jiang Z; Zheng H; Watchko JF; Clemens PR
Gene Ther; 2008 Apr; 15(7):531-6. PubMed ID: 18273052
[TBL] [Abstract][Full Text] [Related]
17. Respective roles of TNF-alpha and IL-6 in the immune response-elicited by adenovirus-mediated gene transfer in mice.
Benihoud K; Esselin S; Descamps D; Jullienne B; Salone B; Bobé P; Bonardelle D; Connault E; Opolon P; Saggio I; Perricaudet M
Gene Ther; 2007 Mar; 14(6):533-44. PubMed ID: 17109009
[TBL] [Abstract][Full Text] [Related]
18. [Development of adenoviral vectors in gene therapy: application to gene transfer in muscles].
Ragot T; Perricaudet M
C R Seances Soc Biol Fil; 1996; 190(1):13-31. PubMed ID: 8881265
[TBL] [Abstract][Full Text] [Related]
19. The short MCK1350 promoter/enhancer allows for sufficient dystrophin expression in skeletal muscles of mdx mice.
Larochelle N; Oualikene W; Dunant P; Massie B; Karpati G; Nalbantoglu J; Lochmuller H
Biochem Biophys Res Commun; 2002 Apr; 292(3):626-31. PubMed ID: 11922612
[TBL] [Abstract][Full Text] [Related]
20. Ovine adenovirus vectors mediate efficient gene transfer to skeletal muscle.
Löser P; Hillgenberg M; Arnold W; Both GW; Hofmann C
Gene Ther; 2000 Sep; 7(17):1491-8. PubMed ID: 11001369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
